InSitu Biologics is an emerging biotech company based in Saint Paul, MN, specializing in the development of innovative drug delivery solutions for localized treatment of pain, cancer, and infection. Their multi-phase, extended-release treatment approach offers a promising solution for addressing unmet needs in the pain management and drug delivery markets.
With products like INSB200, an extended-release pain control solution for peri-operative pain management, and INSB400, an early-development product focused on precise local delivery of cancer drugs over a pre-programmed period of time, InSitu Biologics is poised to make a significant impact in the healthcare industry. Currently in the investigational pre-clinical stage, their groundbreaking technology is approaching Phase 1 clinical trials, presenting a multi-billion dollar opportunity.
Generated from the website